Melanotan II (MT-II) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide. It acts at melanocortin receptors (primarily MC1R, MC3R, and MC4R) to stimulate skin pigmentation and has also been studied for effects on sexual function and libido. Melanotan II is not FDA-approved as a drug. TruVera provides MT-II through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician.

MT-II has two main areas of clinical interest. First, by activating MC1R receptors on melanocytes, it stimulates eumelanin production — the darker, photoprotective pigment — leading to a gradual, natural-looking tan and increased baseline protection against UV-induced skin damage. Second, via MC4R activity in the central nervous system, MT-II has been studied for its ability to support libido and sexual function in both men and women. In early clinical trials, it produced pro-erectile effects in men at low doses and increased sexual desire in women. A clinician will review your goals and health history to determine whether MT-II is appropriate for you.

Melanotan II is administered as a subcutaneous injection — a small-needle injection into the fatty tissue just under the skin, similar to insulin or other peptide protocols. Your care team will provide step-by-step dosing instructions, explain the loading and maintenance phases, and answer any questions about self-injection technique. Dosing typically begins low to assess tolerance before titrating to an effective maintenance dose.

Most patients begin to notice skin darkening within 1–3 weeks of starting the loading protocol, with more significant tanning developing over 4–8 weeks of consistent use. Results vary based on your baseline skin type (Fitzpatrick scale), dose, and degree of incidental UV exposure. Libido-related effects, if experienced, are often reported earlier — sometimes within days of dosing. Your clinician will set realistic expectations based on your specific skin tone and goals during your consultation.

Melanotan II has a well-characterized side effect profile from early clinical trials. The most common effects are nausea and flushing, typically occurring 30–90 minutes after injection, especially during the initial loading phase and at higher doses — these usually diminish as the body adjusts. Spontaneous or prolonged erections (in men) are a known pharmacological effect and should be reported to your clinician if they persist or become uncomfortable. Facial flushing, yawning, and mild fatigue have also been reported. Darkening of existing moles or nevi can occur; any unusual changes in skin lesions should be reported to your clinician promptly. Long-term human safety data beyond short-term trials is limited. Your clinician will review your complete health history before prescribing.

Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol or want to adjust your plan before canceling, your care team is always available to discuss your options.